GSK Stock Analysis: Buy, Sell, or Hold?
GSK - GSK plc American Depositary Shares (Each representing two Ordinary Shares)
$49.89
-0.98 (-1.93%)
▼
5d:
-1.83%
30d:
-4.37%
90d:
-3.16%
BUY
MODERATE Confidence
Analysis Updated: Sep 4, 2026 12:00 AM ET
Earnings: Jul 28, 2026
0d
Get Alerted When GSK Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
💡 BUY OPPORTUNITY: GSK shows positive signals but monitor for confirmation. Market pricing in 1.3% decline. Moderate conviction.
💡 BUY OPPORTUNITY: GSK shows positive signals but monitor for confirmation. Market pricing in 1.3% decline. Moderate conviction.
Long-Term Wealth Forecast (2031)
Based on Analyst Consensus Growth & Historical Valuation
0% (Stagnation)
50% (Hyper Growth)
EST. PRICE IN 2031
$63.09
Based on 4.0% avg growth
INTRINSIC VALUE TODAY
$39.17
Trading above historical range
How this is calculated: We use a Growth Decay Model: starting with analyst consensus growth (adjusted above) and gradually slowing it down to a long-term terminal rate (4%) by Year 5. This provides a more realistic valuation than assuming constant hyper-growth. We then apply a 10.4x Exit PE.
In-depth Analysis How we analyze
Valuation Analysis: GSK is currently trading at $49.89, which is considered oversold relative to its 30-day fair value range of $50.40 to $52.45. The stock's valuation (Forward PE: 10.0) is in line with its historical norms (10.4). Remarkably, the market is currently pricing in an annual earnings decline of 1.3% over the next few years. This aligns with recent fundamental challenges.
Technical Outlook: Technically, GSK is in a downtrend. The price is currently testing key support at $49.66. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: GSK scores 62/100 on our bottoming-setup gauge — the chart has corrected and is stabilizing (RSI reset, momentum turning up), historically a favorable entry zone. Wall Street analysts see significant upside, with an average price target of $58.58 (+17.4%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Technical Outlook: Technically, GSK is in a downtrend. The price is currently testing key support at $49.66. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: GSK scores 62/100 on our bottoming-setup gauge — the chart has corrected and is stabilizing (RSI reset, momentum turning up), historically a favorable entry zone. Wall Street analysts see significant upside, with an average price target of $58.58 (+17.4%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Quick Decision Summary
Current Position
OVERSOLD
Historical Trading Range
$50.40 -
$52.45
Company Quality Score
53/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
88.1%
All Signals
- BULLISH: Price oversold vs 30-day range
- BULLISH: Strong technical setup (62/100)
- BULLISH: High volume confirmation
- BULLISH: Trading below Wall St target ($58.58)
- BULLISH: Bottoming setup score 62/100 — corrected, stabilizing, and turning up
Trading Range Analysis
30-Day Trading Range
$50.40 -
$52.45
Current vs Trading Range
OVERSOLD
Support & Resistance Levels
Support Level
$49.66
Resistance Level
$52.21
Current Trend
Downtrend
Technical data as of
Sep 4, 2026
Fundamental Context
Forward P/E (Next Year Est.)
10.01
Wall Street Target
$58.58
(+17.4%)
Revenue Growth (YoY)
5.3%
Earnings Growth (YoY)
-69.5%
Profit Margin
14.5%
Valuation Discount vs History
-1.3% cheaper
PE vs Historical
10.0 vs 10.4
FAIR
Market-Implied Price Targets
If current PE multiple persists
Implied Growth (YoY):
-1.3%
(market-implied from PE analysis)
1-Year Target
$49.24
(-1%)
2-Year Target
$48.60
(-3%)
3-Year Target
$47.97
(-4%)
3-Yr Target (if PE normalizes)
(PE: 10→10)
$49.86
(0%)
3-Year Scenarios
Using analyst projected EPS growth
Bull:
(PE: 20.2, Growth: 4.0%)
$113.51
(+128%)
Base:
(SPY PE: 10.0, Growth: 4.0%)
$56.14
(+13%)
Bear:
(PE: 8.5, Growth: 4.0%)
$47.72
(-4%)
📈
Valuation based on Current Earnings
RECOVERY PLAY: Stock looks expensive now (16x PE), but valuation improves significantly next year (10x PE) as earnings recover.
Trailing PE: 16.00 | Current EPS (TTM): $3.18
Bull Case
$87.74
(+76%)
Analyst growth 56.8%, PE expands to 17.6
Base Case
$79.76
(+60%)
Market implied 56.8%, PE stable at 16.0
Bear Case
$34.59
(-31%)
Severe decline -20.0%, PE contracts to 13.6
These are projections based on PE multiples and EPS growth scenarios, not predictions. Actual results may vary significantly.
💡
Upside Surprise Potential
If earnings stabilize (0% growth), PE could expand from 10.0 to 10.4
Stabilization Target:
$51.86
(+3.9%)
PE Expansion Potential:
+3.9%
Share & Embed Analysis
Last updated: September 04, 2026 10:00 PM ET
Data refreshes hourly during market hours. Next update: 11:00 PM
Data refreshes hourly during market hours. Next update: 11:00 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is GSK showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Drug Manufacturers - General Stocks
Top-rated stocks in Drug Manufacturers - General by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
LLY
Eli Lilly and Company |
STRONG BUY
31 analysts |
$1315 | 43 HOLD |
|
GILD
Gilead Sciences Inc |
BUY
30 analysts |
$157 | 39 SELL |
|
ABBV
AbbVie Inc |
BUY
28 analysts |
$277 | 51 HOLD |
|
AMGN
Amgen Inc |
HOLD
32 analysts |
$388 | 51 HOLD |
|
BIIB
Biogen Inc |
HOLD
37 analysts |
$236 | 47 HOLD |
